AI Article Synopsis
- Chronic inflammation is linked to cancer development, with high levels of prostaglandin E2 and COX-2 expression identified in several types of cancer, impacting tumor growth and immune response.
- Non-steroidal anti-inflammatory drugs (NSAIDs) are used to lower pain and inflammation by blocking COX-2, which could have implications for cancer treatment.
- This review discusses how NSAIDs and COX-2 inhibitors might be utilized for breast cancer therapy, based on various laboratory studies assessing their effectiveness and potential use alongside other cancer treatments.
Article Abstract
Chronic inflammation plays a crucial role in carcinogenesis. High levels of serum prostaglandin E2 and tissue overexpression of cyclooxygenase-2 (COX-2) have been described in breast, urinary, colorectal, prostate, and lung cancers as being involved in tumor initiation, promotion, progression, angiogenesis, and immunosuppression. Non-steroidal anti-inflammatory drugs (NSAIDs) are prescribed for several medical conditions to not only decrease pain and fever but also reduce inflammation by inhibiting COX and its product synthesis. To date, significant efforts have been made to better understand and clarify the interplay between cancer development, inflammation, and NSAIDs with a view toward addressing their potential for cancer management. This review provides readers with an overview of the potential use of NSAIDs and selective COX-2 inhibitors for breast cancer treatment, highlighting pre-clinical in vitro and in vivo studies employed to evaluate the efficacy of NSAIDs and their use in combination with other antineoplastic drugs.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11188899 | PMC |
| http://dx.doi.org/10.14202/vetworld.2024.1052-1072 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Multigenerational effects of individual and binary mixtures of two commonly used NSAIDs on Daphnia carinata.
Ecotoxicology
January 2025
Ecotoxicology Research group, School of Science, RMIT University, Melbourne, VIC, Australia.
Pharmaceuticals, including non-steroidal anti-inflammatory drugs (NSAIDs) like ibuprofen (IBU) and naproxen (NPX), are widely used for medical purposes but have also become prevalent environmental contaminants. However, there is limited understanding of their effects on aquatic organisms, especially regarding multigenerational and mixture exposures. This study aimed to evaluate the toxicological impacts of ibuprofen and naproxen, individually and in combination, on three generations of Daphnia carinata, a freshwater organism.
View Article and Find Full Text PDFDasatinib-induced colitis in a patient with chronic myeloid leukaemia.
BMJ Case Rep
January 2025
Department of Digestive Health, Gold Coast University Hospital, Gold Coast, Australia, Gold Coast Hospital and Health Service, Southport, Queensland, Australia.
Dasatinib is a common treatment for chronic myeloid leukaemia with numerous side effects including gastrointestinal. We report a woman in her 50s who presented with haematochezia, weight loss and a positive faecal occult blood test. She was being treated for chronic myeloid leukaemia with dasatinib without the use of any concurrent medications, including non-steroidal anti-inflammatory drugs.
View Article and Find Full Text PDFFabrication of novel multifunctional copper-functionalized hemp fibers to remove anionic dye and non-steroidal anti-inflammatory drugs from wastewaters.
Chemosphere
January 2025
Department of Industrial Engineering, University of Salerno, Via Giovanni Paolo II, 132, 84084 Fisciano, Salerno, Italy.
This research aims to design a novel selective and multifunctional adsorbent based on Al/Cu modified hemp fibres as a novel and multifunctional adsorbent for removing different classes of pollutants. The adsorbent, which was widely characterized, was shown to be more effective in removing anionic dyes compared to cationic ones. Among the tested dye, methyl orange was selected to understand how different parameters, such as temperature (20-80°C), contact time, pH (2-12), initial dye concentration (50-300 ppm), salinity and adsorbent dosage (1-10 g/L) affect the removal capacity.
View Article and Find Full Text PDFUpdates on Recent Advances in the Therapy of Adult Psoriatic Disease.
Curr Rheumatol Rev
January 2025
University of Toronto, Psoriatic Arthritis Program, University Health Network, Toronto Western Hospital, Toronto, Ontario, Canada.
Psoriatic arthritis (PsA) is a heterogeneous inflammatory disease with various joint and skin manifestations and multiple associated comorbidities. The management of PsA is important not only in controlling disease activity and preventing subsequent damage but also in improving the quality of life and reducing mortality. Over the years, numerous drugs have been introduced into the therapeutic armamentarium of the disease.
View Article and Find Full Text PDFEfficacy and safety of jaktinib hydrochloride tablets in active axial spondyloarthritis: a multicentre, randomised, double-blind, placebo-controlled phase II clinical trial.
RMD Open
January 2025
Department of Rheumatology, Ren Ji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Objective: The objective of this study is to evaluate the efficacy and safety of jaktinib hydrochloride tablets (jaktinib), a Janus kinase inhibitor, in patients with active radiographic axial spondyloarthritis (r-axSpA).
Methods: Adults with active r-axSpA who met modified New York criteria and had an inadequate response to non-steroidal anti-inflammatory drugs were randomised 1:1:1 to receive jaktinib 75 mg two times per day, 100 mg two times per day, or placebo. The primary and key secondary endpoints were Assessment of SpondyloArthritis international Society 20 (ASAS 20) and ASAS 40 responses, respectively, at week 16.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!